INEBILIZUMAB

( DrugBank: Inebilizumab / KEGG DRUG: Inebilizumab )

---

8 diseases

11. 重症筋無力症

---

臨床試験数 : 525 / 薬物数 : 355 - (DrugBank : 80) / 標的遺伝子数 : 75 - 標的パスウェイ数 : 139 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,898 / 薬物数 : 2,785 - (DrugBank : 360) / 標的遺伝子数 : 265 - 標的パスウェイ数 : 239 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

46. 悪性関節リウマチ

---

臨床試験数 : 4,743 / 薬物数 : 3,042 - (DrugBank : 389) / 標的遺伝子数 : 205 - 標的パスウェイ数 : 253 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

49. 全身性エリテマトーデス

---

臨床試験数 : 1,414 / 薬物数 : 1,077 - (DrugBank : 181) / 標的遺伝子数 : 130 - 標的パスウェイ数 : 209 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

51. 全身性強皮症

---

臨床試験数 : 740 / 薬物数 : 813 - (DrugBank : 165) / 標的遺伝子数 : 140 - 標的パスウェイ数 : 231 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

53. シェーグレン症候群

---

臨床試験数 : 448 / 薬物数 : 436 - (DrugBank : 104) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 185 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

95. 自己免疫性肝炎

---

臨床試験数 : 63 / 薬物数 : 80 - (DrugBank : 30) / 標的遺伝子数 : 24 - 標的パスウェイ数 : 116 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

300. IgG4関連疾患

---

臨床試験数 : 81 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 152 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries